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Abstract 
Background: Patients with type 2 diabetes mellitus (T2DM) from Latin American countries face challenges in access 
to healthcare, leading to under-diagnosis, under-achievement of glycemic target, and long-term complications. Early 
diagnosis and treatment initiation are of paramount importance in this population due to the high prevalence of risk 
factors such as obesity and metabolic syndrome. The VERIFY study in patients with newly diagnosed T2DM (across 34 
countries), assessed the normoglycemic durability (5 years), with early combination (EC) therapy approach versus the 
traditional stepwise approach of initiating treatment with metformin monotherapy (MET). Here we present the results 
from the VERIFY study for participants from eight countries in Latin America.
Methods: Newly diagnosed adult patients with T2DM, HbA1c 6.5–7.5% and body-mass index (BMI) of 22–40 kg/m2 
were enrolled. The primary endpoint was time to initial treatment failure (TF; HbA1c ≥ 7.0% at two consecutive sched-
uled visits 13 weeks apart). Time to second TF was evaluated when patients in both groups were receiving and failing 
on the vildagliptin combination. Safety and tolerability were also assessed for both treatment approaches during the 
study.
Results: A total of 537 eligible patients (female, 58.8%) were randomly assigned to receive either EC (n = 266) or MET 
(n = 271). EC significantly reduced the relative risk of time to initial TF by 47% versus MET [HR (95% CI) 0.53 (0.4, 0.7) 
p < 0.0001]. Overall, 46.4% versus 66.3% of patients achieved the primary endpoint in the EC and MET groups, with a 
median [interquartile range (IQR)] time to TF of 59.8 (27.5, not evaluable) and 33.4 (12.2, 60.1) months, respectively. The 
risk for time to second TF was 31% lower with EC (p < 0.0092). A higher proportion of patients receiving EC maintained 
durable HbA1c < 7.0%, < 6.5%, and < 6.0%. Both treatment approaches were well tolerated, and only 3.2% of partici-
pants discontinued the study due to adverse events. All hypoglycemic events (EC: n = 7 and MET: n = 3) were single, 
mild episodes and did not lead to study discontinuation.
Conclusion: Similar to the global population, long-term clinical benefits were achieved more frequently and without 
tolerability issues with EC versus standard-of-care MET in this Latin American sub-population.
This study is registered with ClinicalTrials.gov, NCT01528254.
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Background
Diabetes presents a major health crisis in Latin Ameri-
can countries, being one of the leading causes of death 
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an estimated 32 million adults from Latin America had 
diabetes, and the prevalence is projected to increase 
by 55% in the next 25  years [2]. The disproportion-
ate increase of diabetes in Latin America compared 
with other Western countries can be attributed to the 
genetic, socioeconomic, and environmental predisposi-
tion of this regional population for various risk factors 
of type 2 diabetes mellitus (T2DM), such as obesity, 
insulin resistance and other metabolic disorders such 
as elevated fasting plasma glucose, impaired glucose 
tolerance, dyslipidemia and low high-density lipopro-
tein cholesterol levels [3]. These risk factors are pre-
dominant in the Latin American population, with 50% 
of adults being obese and one-third of the population 
having metabolic syndrome [4].
Diabetes imposes a high economic burden in Latin 
American countries, incurring a total cost of USD 70 bil-
lion annually and constituting up to 6–24% of the annual 
total expenditure of the national health budgets [2]. The 
heterogeneity in the economic vulnerabilities towards 
diabetes across the region [5] might be due to inequali-
ties in the socioeconomic aspects among countries in the 
Latin American region [6]. Socioeconomic conditions in 
Latin America present several public health challenges 
for diabetes care, such as low disease awareness; inad-
equate diagnosis; treatment, and preventive measures; 
and limited access to health care facilities [5, 7, 8]. Diag-
nosis is often delayed as the prevalence of undiagnosed 
patients ranges from 10.3 to 50% in this region [9]. Access 
to treatment is also a major challenge [10], and less than 
50% of patients receiving treatment achieve their glyce-
mic targets [11]. In addition, diabetes-related compli-
cations predominate in more than 80% of patients with 
T2DM in this region [11].
Achieving glycemic targets early in the disease con-
tinuum leads to a legacy effect of sustained reduction in 
the risk of complications such as myocardial infarction, 
death due to any cause, and microvascular disease [12]. 
A meta-analysis of studies comparing early intensifica-
tion using combination therapy versus monotherapy 
showed better glycemic control with early combination 
therapy [13]. To date, the most compelling evidence sig-
nifying the long-term benefits of early intervention with 
a combination treatment over a 5-year period is available 
from the VERIFY study [14]. The VERIFY study aimed 
to determine whether an early combination strategy 
(building on the molecules with well-established safety 
and efficacy profiles such as vildagliptin and metformin 
[15–17]) could provide more durable glycemic and clini-
cal benefits compared with sequentially intensified ini-
tial metformin monotherapy in treatment-naïve patients 
with newly diagnosed T2DM and mild hypoglycemia (a 
glycated hemoglobin [HbA1c] level of 6.5%–7.5%). Here, 
we present a sub-analysis of the VERIFY study in patients 
with T2DM from eight Latin American countries.
Subjects and methods
Study design
VERIFY was a phase IV, randomized, double-blind, 
multi-ethnic, two-arm parallel-group study including 
treatment-naïve patients with T2DM. Details regarding 
the study design have been previously published [18].
Briefly, after screening, the eligible patients entered 
a 3-week “run-in period” during which metformin was 
individually initiated and/or up-titrated. Patients who 
were able to tolerate a metformin dose of 1000  mg or 
higher were randomized 1:1 to receive either early combi-
nation (vildagliptin 50 mg plus metformin up to 1000 mg 
twice-daily) therapy or metformin monotherapy (up to 
1000  mg with placebo twice daily) in period 1. Patients 
with initial loss of glycemic control (determined by two 
consecutive measurements of HbA1c ≥ 7.0% after ran-
domization, 13 weeks apart), while receiving metformin 
monotherapy, received vildagliptin as add-on treatment 
during period 2. Those randomized to the early combi-
nation therapy continued to receive the same treatment. 
Further therapy intensification with open-label insu-
lin in addition to the combination therapy was allowed 
after treatment failure in period 2, following local dia-
betes treatment guidelines and at the physician’s discre-
tion (period 3). Patients receiving therapy intensification 
with blood glucose-lowering drugs, other than insulin in 
period 3, were discontinued from the study.
Participants
Adult patients with centrally confirmed HbA1c of 6.5–
7.5% and body  mass index (BMI) of 22–40  kg/m2 were 
enrolled by 53 centers in eight Latin American countries 
(Argentina, Brazil, Colombia, Dominican Republic, Gua-
temala, Mexico, Panama, and Peru).
Patients receiving glucose-lowering treatment (except 
metformin ≤ 2000  mg daily within one month prior to 
screening) or using weight-loss medications within three 
months prior to screening were excluded. Additionally, 
individuals with contraindications for use of either of the 
study medications, such as those with chronic liver dis-
ease or ongoing congestive heart failure (New York Heart 
Association Functional Classification III–IV) and those 
with pregnancy or lactation in progress, were excluded.
Outcomes
The primary efficacy endpoint was the time to confirmed 
initial treatment failure, defined as HbA1c ≥ 7.0% at two 
consecutive planned visits, 13  weeks apart from rand-
omization (the earliest possible failure time is 6 months 
post-randomization) [14]. Initial treatment failure was 
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compared between the patients receiving early com-
bination (vildagliptin plus metformin) and metformin 
monotherapy.
The initial treatment failure was also compared 
between the two treatment groups across the various 
baseline subgroups including age, gender, race, HbA1c 
level, BMI and smoking status.
The secondary endpoints included time to second 
treatment failure, defined as two consecutive values of 
HbA1c ≥ 7.0% when all patients were receiving combi-
nation therapy; change in HbA1c over time, safety and 
tolerability.
Glycemic control with the two treatment approaches 
was evaluated over the study duration comparing pro-
portion of patients with HbA1c below 7.0, 6.5 and 6.0%. 
Changes in body weight throughout the study period was 
also compared between the two treatment groups.
Treatment-emergent adverse events (AEs) and seri-
ous adverse events (SAEs), including pregnancies and 
medically significant changes in biochemical and other 
laboratory parameters, were recorded per initial treat-
ment approach throughout the study along with their 
severity and relationship to blinded study drug. Hypo-
glycemic events were separately reported. All patients 
were provided with a home blood glucose monitor. 
At the first visit, patients were trained to monitor their 
blood glucose as well as detect and report hypoglycemia. 
Apart from typical symptoms of hypoglycemia, a capil-
lary whole blood glucose level of < 50 mg/dL (< 2.8 mM), 
corresponding to a plasma glucose level of < 56  mg/dL 
(< 3.1  mM), was considered as a hypoglycemic event. 
Confirmed hypoglycemic events were also classified 
based on their severity (G1/G2); i.e., those necessitating 
assistance were considered to be of Grade 2 severity.
Statistical analysis
Detailed pre-defined statistical analysis plan was pub-
lished prior to the primary analysis and unblinding 
[19]. The time to initial and second treatment failures 
were measured with Cox proportional hazards regres-
sion model which included treatment approach and 
geographical region as factors and baseline HbA1c as a 
covariate. Subgroup analyses of the initial treatment fail-
ure were done using a Cox regression analyses. Cumula-
tive probabilities of initial and second treatment failures 
over time were assessed using Kaplan–Meier estimates. 
Patients receiving at least one randomized dose of either 
study drug or with at least one post-randomization visit 
for glycemic efficacy contributed to the Kaplan–Meier 
comparator in each group. Safety outcomes were ana-
lyzed for all patients who received at least one dose of 
randomized study medication (vildagliptin or placebo). 
AEs were summarized as number and proportions of 
patients having any AE by treatment group and clas-
sified by each primary system organ class. A p value of 
0.05 (2-sided) was considered significant. The statistical 




The VERIFY global population included 2001 rand-
omized patients [14], 537 of whom were from the Latin 
American region. Of 1258 patients screened from this 
region, 55.8% (n = 703) failed the screening due to 
HbA1c value outside of the indicated glycemic range 
(HbA1c < 6.5% or > 7.5%); 176 (13.9%) had HbA1c > 7.5% 
with an average HbA1c of 8.9%, ranging from 7.7 to 
15.0% (Fig. 1).
A total of 266 patients received early combination (vild-
agliptin plus metformin), and 271 patients received ini-
tial monotherapy. Overall, 80.8% (n = 215) of patients in 
the early combination and 78.6% (n = 213) of patients in 
initial monotherapy group completed the study. Approxi-
mately 20.3% (n = 109) of the study population discon-
tinued the study prematurely, mostly for administrative 
reasons (n = 54) such as moving to a new city/country for 
work or studies or general work-related burden/ unable 
to attend further visits.
The mean (SD) age of the Latin American study pop-
ulation was 52.7 (9.9) years, with a mean (SD) BMI of 
31.0 (4.7) kg/m2. The absolute weight of the patients 
ranged between 44.8 and 142.4 kg. Of the 537 study par-
ticipants, 316 (58.8%) were females. One in 10 patients 
(10.2%, n = 55) was diagnosed with T2DM before the 
age of 40 years. The majority (80.8%, n = 434) of patients 
included were aged between 40 and 65  years at study 
enrollment. Among the 537 patients randomized, Native 
American (39%) or Caucasian (35%) participants were 
predominant. A total of 27.9% (n = 150) of the population 
had HbA1c ≥ 7.0% at baseline, and patients had a median 
[inerquartile range (IQR)] duration of diabetes of 4.3 (1.3, 
11.5) months (Table 1).
Outcomes
At the end of 5 years, 46.4% (n = 121) of patients in the 
early combination group had met the criteria for ini-
tial treatment failure compared with 66.3% (n = 177) in 
the monotherapy group. Similar to the global results, 
the median (IQR) time to initial treatment failure was 
59.8 (27.5, not evaluable) months in the early combina-
tion group compared with 33.4 (12.2, 60.1) months in 
the monotherapy group. A significant reduction in the 
risk for time to initial treatment failure was observed in 
the early combination group compared with monother-
apy group over the 5-year study duration [hazard ratio 
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(HR) 0.53 [95% confidence interval (CI): 0.42–0.67); 
p < 0.0001] (Fig. 2a, b).
The subgroup analysis for time to initial treatment 
failure for all pre-defined baseline variables, such as 
age, HbA1c at screening or race, with both treatment 
approaches is presented in Fig. 3. Across all pre-defined 
subgroups, the risk for initial treatment failure was 
lower with early combination therapy.
During period 2, 33.7% (n = 88) of patients in the 
early combination group experienced a secondary 
treatment failure, versus 43.4% (n = 116) of patients in 
the monotherapy group. A significant reduction in risk 
of secondary treatment failure was observed with the 
early combination group compared with the monother-
apy group [HR (95% CI) 0.69 (0.52, 0.91); p = 0.0092] 
(Fig. 4). Additionally, a higher proportion of patients in 
the early combination group compared with the initial 
monotherapy group had HbA1c values < 7.0%, < 6.5% 
and < 6.0% over five years (Fig. 5a–c).
Across the study period, body weight remained sta-
ble in both treatment groups. The median (IQR) body 
weight at baseline was 77.6 (68.3–91.0) kg and at the 
end of study was 77.0 (67.9–89.9) kg (Additional file 1: 
Figure S1).
The overall safety and tolerability profiles were simi-
lar between treatment approaches, with no unexpected 
safety findings reported. The incidence of AEs and SAEs 
over five years among Latin American participants 
between the two treatment approaches were 240 (89.8%) 
and 37 (13.8%), respectively, in the combination treat-
ment group and 230 (85.2%) and 41 (15.2%), respectively, 
in the initial monotherapy group. Most of the AEs were 
of mild nature and a small fraction of AEs was reported 
to be related to the study treatment (< 4%). Only 2.6% 
(n = 7) of patients in early combination and 3.7% (n = 10) 
of patients in initial monotherapy group discontinued 
the treatment due to AEs. Majority of the drug-related 
AEs were gastrointestinal disorders likely to be related to 
metformin. Four patients in each group died during the 
study, but no deaths were considered to be related to any 
of the study drugs (Table 2).
Hypoglycemic events were reported in seven patients 
in the early combination group and three in the initial 
monotherapy group, all of which were single events of 
grade 1 severity and did not lead to study discontinu-
ation. One of the hypoglycemic events in each treat-
ment group occurred during insulin treatment after 33 
and 51  months in individuals whose diabetes rapidly 
Fig. 1 Patients disposition. HbA1c glycated haemoglobin. * intolerant to at least 1000 mg daily metformin or not compliant
Page 5 of 13Vencio et al. Diabetol Metab Syndr           (2021) 13:68  
progressed. One participant from this Latin American 
region reported a pregnancy, and consequently, the study 
treatment (vildagliptin plus metformin) was permanently 
discontinued; the participant delivered a healthy baby at 
term.
Discussion
This regional analysis of the VERIFY study in Latin 
American participants demonstrated that early combina-
tion therapy with vildagliptin plus metformin improved 
glycemic durability in patients with newly diagnosed 
T2DM compared with the standard-of-care initial met-
formin monotherapy followed by sequential combina-
tion with vildagliptin. The early combination therapy 
approach among Latin American participants with a low 
diagnostic HbA1c (6.5%–7.5%) significantly reduced the 
risk of initial treatment failure by 47% compared with 
metformin monotherapy throughout the 5-year study 
duration. Early combination approach also reduced the 
risk of secondary treatment failure by 31% compared 
with timely and immediate intensification of metformin 
monotherapy based on the mandate as per the study 
protocol. In addition, the outcomes of this sub-analysis 
showed the applicability of the benefits of early combina-
tion therapy approach across the sub-groups of patients 
in the Latin American region. Overall, the findings of this 
regional analysis are consistent with those of the VERIFY 
global study, despite the distinct predisposing genetic 
Table 1 Patient characteristics and disposition
Baseline refers to randomization visit
HbA1c glycated hemoglobin, BMI body mass index, FPG fasting plasma glucose, GFR glomerular filtration rate, IQR interquartile range, SD standard deviation, T2DM 
type 2 diabetes mellitus
a Baseline values were obtained on screening (day 1) or at a later visit (scheduled or unscheduled) if the Day 1 measurements were missing. Two patients in the early 
combination therapy group did not have baseline HbA1c and fasting plasma glucose measurements on or prior to randomization
b Baseline GFR was calculated using the Modification of Diet in Renal Disease Study equation. Serum creatinine and body weight measurements were obtained on 
Day 1 or at a later visit (scheduled or unscheduled) if the Day 1 measurements were missing









Age (years), mean (SD) 52.0 (10.0) 53.4 (9.7) 52.7 (9.9) 54.3 (9.4)
Age group, n (%)
 < 40 31 (11.7) 24 (8.9) 55 (10.2) 159 (8.0)
 40 −  < 65 214 (80.5) 220 (81.2) 434 (80.8) 223 (11.1)
  ≥ 65 21 (7.9) 27 (10.0) 48 (8.9) 1619 (80.9)
 Women, n (%) 153 (57.5) 163 (60.1) 316 (58.8) 1060 (53.0)
Predominant race, n (%)
 Native American 102 (38.3) 107 (39.5) 209 (38.9) 210 (10.5)
 Caucasian 96 (36.1) 91 (33.6) 187 (34.8) 1217 (60.8)
 Median (IQR) duration of T2DM (months) 4.2 (1.6, 11.1) 4.4 (1.1, 11.9) 4.3 (1.3, 11.5) 3.3 (0.9, 10.0)
HbA1c (%)a
 Mean (SD) 6.7 (0.5) 6.7 (0.5) 6.7 (0.5) 6.7 (0.5)
 ˂7.0%, n (%) 191 (71.8) 196 (72.3) 387 (72.1) 1427 (71.3)
  ≥ 7.0%, n (%) 75 (28.2) 75 (27.7) 150 (27.9) 572 (28.6)
 Median (IQR) FPG (mmol/L)a 6.6 (5.8, 7.4) 6.6 (5.8, 7.5) 6.6 (5.8, 7.5) 6.9 (6.1, 7.8)
BMI (kg/m2)
 Mean (SD) 31.0 (4.6) 31.0 (4.7) 31.0 (4.7) 31.1 (4.7)
 < 30 kg/m2, n (%) 122 (45.9) 123 (45.4) 245 (45.6) 875 (43.7)
 ≥ 30 kg/m2, n (%) 144 (54.1) 148 (54.6) 292 (54.4) 1126 (56.3)
GFR (mL/min/1.73  m2)b
 Normal (˃80) 202 (75.9) 217 (80.1) 419 (78.0) 1321 (66.1)
 Mild (≥ 50– ≤ 80) 64 (24.1) 54 (19.9) 118 (22.0) 670 (33.5)
 Median (IQR) weight (kg) 77.8 (69.0, 92.5) 78.4 (68.0, 90.0) 78.0 (68.5, 91.5) 84.3 (72.3, 97.0)
Current smokers, n (%) 32 (12.0) 29 (10.7) 61 (11.4) 290 (14.5)
Discontinued study participation prematurely, n (%) 51 (19.2) 58 (21.4) 109 (20.3) 403 (20.1)
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and environmental characteristics of this high-risk pop-
ulation and inclusion of a relatively large proportion of 
unique, infrequently studied patients of Native Hispanic 
American origin[3].
The diverseness of baseline characteristics confirms 
that the VERIFY study protocol genuinely allowed enroll-
ment of a globally heterogeneous population reflec-
tive of currently diagnosed individuals with diabetes. 
In Latin America, as in other global regions outside 
Northern Europe [20], a deeper analysis of the glycemic 
data from the screening phase reverberates the chal-
lenges in accurate, early and timely diagnosis of T2DM 
based on glycemia as reported for Latin America [5, 7]. 
Therefore, in this region where there is less-structured 
public healthcare infrastructure, socioeconomic inequal-
ity, and limited access to care, it is sensible that recom-
mendations and procedures facilitate early diagnosis and 
intervention.
The majority of the Latin American sub-population 
from the VERIFY study were relatively young at the 
time of T2DM diagnosis, between the age of 40 and 
65  years, which corresponds to the age range that has 
been reported to have the sharpest rise in diabetes prev-
alence in many Latin American countries (Argentina, 
Chile, Uruguay, and Peru) [21]. The overall inclusion 
of approximately 10% of young-onset diabetes (YOD) 
patients (diagnosed before the age of 40  years) in Latin 
America was similar to the overall VERIFY global study 
population, whereas the highest proportion of YOD was 
enrolled from Asia [22]. Although the VERIFY study pro-
tocol had limited, if any gender-specific exclusion criteria 
beyond those related to current pregnancy and breast-
feeding, the even more pronounced predominance of 
female participants in this regional sub-population (Latin 
American: 59% versus global: 53%) suggests increased 
disease awareness and health-seeking behavior among 
women compared to men, supporting similar observa-
tions from previous real-world studies from the Latin 
American region [11]. Therefore, the study population 
from Latin America included in our sub-analysis repre-
sented the overall current demographics of those with 
newly-diagnosed T2DM within the region.
Obesity in Latin American countries is highly preva-
lent and is influenced by heterogeneous socioeconomic 
factors such as lifestyle and diet [23], which may have 
been the underlying reason for the wide range of body 
weight (with identical mean BMI value) versus the global, 
Fig. 2 a Primary treatment failure* among Latin American patients randomized to early combination versus initial monotherapy. CI confidence 
interval, HR hazard ratio, LatAm Latin America. *Primary treatment failure is defined as HbA1c ≥ 7.0% at two consecutive scheduled visits, starting 
from 13 weeks after randomization. The time to initial treatment failure is the time from randomization to the second consecutive scheduled visits 
with HbA1c ≥ 7.0%. Patients who discontinued the study for any reason during period 1 were censored at the date of discontinuation. Patients 
with HbA1c < 7.0% (or whose measurement ≥ 7.0% was not confirmed at next scheduled visit) were censored at the date of last study visit. The 
Kaplan–Meier estimates were performed for patients who had received at least one randomized medication and one post-randomization efficacy 
parameter assessed. b Primary treatment failure* among all patients from VERIFY randomized to early combination versus initial monotherapy. 
CI, confidence interval; HR, hazard ratio. *Primary treatment failure is defined as HbA1c ≥ 7.0% at two consecutive scheduled visits, starting from 
13 weeks after randomization. The time to initial treatment failure is the time from randomization to the second consecutive scheduled visits 
with HbA1c ≥ 7.0%. Patients who discontinued the study for any reason during period 1 were censored at the date of discontinuation. Patients 
with HbA1c < 7.0% (or whose measurement ≥ 7.0% was not confirmed at next scheduled visit) were censored at the date of last study visit. The 
Kaplan–Meier estimates were performed for patients who had received at least one randomized medication and one post-randomization efficacy 
parameter assessed
(See figure on next page.)
Table 2 Adverse events by preferred terms in the Latin 
American study population
Patients with multiple adverse events under one treatment approach were 
counted only once in the adverse event category for that treatment approach
AE adverse events






Patients with at least one 
AE
240 (89.8) 230 (85.2)
 Diarrhea 47 (17.6) 36 (13.3)
 Back pain 41 (15.4) 32 (11.9)
 Influenza 41 (15.4) 24 (8.9)
 Arthralgia 40 (15.0) 43 (15.9)
 Urinary tract infection 34 (12.7) 29 (10.7)
 Hypertension 34 (12.7) 39 (14.4)
 Nasopharyngitis 33 (12.4) 38 (14.1)
 Headache 31 (11.6) 28 (10.4)
 Pain in extremity 31 (11.6) 42 (15.6)
 Anxiety 18 (6.7) 31 (11.5)
 Dyslipidemia 23 (8.6) 27 (10.0)
 Pharyngitis 21 (7.9) 22 (8.1)
 Hypertriglyceridemia 20 (7.5) 10 (3.7)
 Bronchitis 16 (6.0) 13 (4.8)
 Gastroenteritis 14 (5.2) 16 (5.9)
 Abdominal pain 13 (4.9) 14 (5.2)
 Hepatic steatosis 13 (4.9) 9 (3.3)
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observed in this Latin American sub-population of VER-
IFY. An earlier real-world study reported that the major-
ity of patients with T2DM from Latin America were 
obese (BMI ≥ 30  kg/m2), and only 46.2% of these obese 
patients achieved glycemic control with sequential treat-
ment intensification [11]. However, in our regional as 
well as global study populations, the early combination 
approach showed glycemic benefits in both sub-groups 
of patients with BMI ≥ 30 kg/m2 and < 30 kg/m2. In addi-
tion, the overall body weight of the study participants 
remained stable over 5  years, with both the treatment 
approaches.
Earlier studies with the traditional sequential treat-
ment intensification approach in clinical practice among 
patients from Latin America have shown that only 
25–30% of patients achieved their glycemic target [10, 
11]. A recent review of Latin American studies showed 
that non-attainment of glycemic control is primarily 
associated with longer duration of disease, a complex 
regimen, and inadequate access to healthcare and insur-
ance coverage [9]. In this sub-analysis, 53.6% of patients 
using early combination therapy achieved and sustained 
glycemic control over a long term.
The current diabetes management guidelines from 
the Latin American Diabetes Association (ALAD, Aso-
ciación Latinoamericana de Diabetes) recommend 
early combination therapy only in patients with diag-
nostic HbA1c value of > 8.0% [24]. However, in clinical 
practice in Latin America, failing monotherapy treat-
ment is intensified using combination therapies only 
Fig. 3 Subgroup analysis of time to initial treatment failure. BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration 
rate, HR hazard ratio. HRs and the associated CIs and p values were obtained from a Cox proportional hazards model containing terms for 
treatment approach, geographical region, and baseline HbA1c. Significance was established on the basis of a two-sided 0.05 significance level. 
The treatment-by-subgroup interaction p values are provided for tests of homogeneity of between-group differences among subgroups, with 
no adjustment for multiple testing. The p value for treatment comparison in the overall population is also provided. BMI body mass index, CI 
confidence interval, GFR glomerular filtration rate, HbA1c glycated hemoglobin, HR hazard ratio, N total number of patients considered for each 
subgroup analysis, n number of patients with relevant results within each subgroup
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at an average HbA1c of 8.5% [25]. In addition, < 40% 
of patients receive combination oral antidiabetics 
within the first 2  years of T2DM diagnosis [10]. In a 
cross-sectional study from Colombia, of 363 patients 
with T2DM with a median HbA1c of 6.8%, only 43.8% 
received combination therapy at their first consulta-
tion, and therapeutic inertia was reported in > 50% of 
the consultations. Interestingly, the risk of therapeutic 
inertia at follow-up consultations was low with better 
HbA1c control [26]. In 2017, a survey-based study from 
Brazil showed that 75% of physicians do not consider 
combination therapy at treatment initiation and prefer 
to use it as a second-line therapy [8]. These observa-
tions indicate the presence of therapeutic inertia as one 
of the major barriers to optimized management of gly-
cemia [27].
Based on the clinical benefits of early combination 
therapy demonstrated by the VERIFY global study, the 
American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) have 
updated their consensus statement suggesting that 
healthcare providers should engage in shared decision 
making around initial combination therapy in new-
onset cases of T2DM [28]. Similarly, the latest update 
of the Brazilian guidelines recommends early combina-
tion therapy in treatment-naïve patients with HbA1c 
6.5–7.5% to delay treatment failure and improve glyce-
mic control based on the clinical benefits [29].
Fig. 4 Secondary treatment failure* among patients with early combination versus initial monotherapy followed by vildagliptin addition. CI 
confidence interval, HbA1c glycated hemoglobin; HR, hazard ratio. *Secondary treatment failure is defined as two consecutive scheduled visits 
with HbA1c ≥ 7.0% during period 2 (i.e., after period 1 comparing metformin monotherapy versus early combination therapy with metformin 
and vildagliptin and up to end of period 2 when both groups are on combination therapy after primary treatment failure. The time to secondary 
treatment failure is the number of days from randomization to the second confirmed HbA1c ≥ 7.0% during consecutive scheduled visits, three 
months apart, in period 2. The Kaplan Meier estimates were performed for patients who had received at least one randomized medication and one 
post-randomization efficacy parameter assessed. Patients who had no event and discontinued the study for any reason during period 1 or period 2 
were censored at the date of discontinuation. Patients who entered period 3 from period 1 were censored to last study visit prior to start of period 
3. Two-sided p value was obtained from a Cox proportional hazards model containing terms for treatment approach. Baseline HbA1c was the value 
obtained on Day 1, or the value obtained at an earlier visit (scheduled or unscheduled) which was closest to Day 1, if Day 1 measurement was 
missing
(See figure on next page.)
Fig. 5 a Success rate of early combination and initial monotherapy approaches at cut-off HbA1c 7.0%. HbA1c glycated hemoglobin. b Success rate 
of early combination and initial monotherapy approaches at cut-off HbA1c 6.5%. HbA1c, glycated hemoglobin. c Success rate of early combination 
and initial monotherapy approaches at cut-off HbA1c 6.0%. HbA1c glycated hemoglobin
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This Latin American sub-analysis of the VERIFY study 
has shown that with early combination therapy, patients 
achieved a durable glycemic control, with a higher pro-
portion maintaining HbA1c levels below 7.0, 6.5, and 
6.0% over 5 years compared with those who received ini-
tial metformin monotherapy across various sub-groups. 
These findings suggest that regardless of the disparities 
in the social situation in Latin America, an early com-
bination strategy can help achieve glycemic control in 
patients newly diagnosed with T2DM in this region.
Strengths and limitations
The observed glycemic durability and improved safety 
parameters confirm the clinical applicability (and gen-
eralizability) of the previously presented global results 
of the benefits of early combination therapy in the Latin 
American population with newly diagnosed T2DM. 
These findings strengthen the global clinical applicability 
of the VERIFY study results. The long-term study dura-
tion of 5 years is one of the main strengths of the VER-
IFY study and its sub-analysis. The pragmatic design of 
the study made it feasible to include a study population 
reflective of the current and characteristically diverse 
T2DM population in the Latin American region, includ-
ing patients with YOD, obese individuals, and a pre-
dominance of female patients who otherwise so often 
are excluded from clinical studies with no valid reasons 
[30–32].
Conclusion
The significant and consistent improvement in the 
long-term glycemic durability with early combination 
approach compared with initial metformin monotherapy 
in patients with newly diagnosed T2DM shown by the 
VERIFY study was also observed in this Latin Ameri-
can regional analysis. Considering these glycemic ben-
efits, early combination treatment could be an effective 
approach to address the challenge in attaining the opti-
mal therapeutic target for patients in this region.
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